First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-012729 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Kristoffer Staal Rohrberg und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Programmed Cell Death 1 Receptor, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
This first-in-human clinical study explored lomvastomig, an immunoglobulin G1-based Fc-silenced bispecific antibody that simultaneously blocks the immune checkpoint receptors programmed cell death protein 1 (PD-1) and T-cell immunoglobulin domain and mucin domain-3.
Methods
Lomvastomig was characterized in cell cultures and preclinically in cancer mouse models. The phase 1, open-label, multicenter clinical study of lomvastomig included a dose-escalation part in patients with advanced and/or metastatic solid tumors and an expansion part with four tumor-specific cohorts, which enrolled checkpoint inhibitor (CPI)-experienced patients with melanoma and non-small-cell lung cancer (NSCLC) and CPI-naïve patients with SCLC and esophageal squamous cell carcinoma (ESCC). Primary and secondary objectives included safety/tolerability, maximum tolerated dose (MTD)/recommended dose for expansion (RDE), pharmacokinetics, drug receptor occupancy, and antitumor activity.
Results
39 and 95 patients were enrolled in the dose-escalation and expansion parts, respectively. Lomvastomig was well tolerated up to the highest tested dose of 2,100 mg every 2 weeks (Q2W). One dose-limiting toxicity was reported at 1,200 mg (grade 3 troponin T increase). No MTD was reached, and 2,100 mg Q2W was established as the RDE. Linear pharmacokinetics across the studied dose range suggested target saturation. Peripheral blood drug receptor occupancy on CD3+ and CD8+ was saturated at >90% throughout treatment for doses ≥70 mg. Objective responses were observed at 2,100 mg lomvastomig during dose-escalation (21%; n=19), and in the CPI-experienced melanoma (8%, n=38) and CPI-naïve ESCC (20%, n=15) expansion cohorts.
Conclusions
Lomvastomig had a tolerable and manageable safety profile at 2,100 mg Q2W. Clinical activity was limited in CPI-experienced patients with melanoma and NSCLC, while an encouraging signal was observed in CPI-naïve patients with ESCC. Trial registration number NCT03708328 (registration date: 2018–10-09).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Medical Oncology, Clinica Universidad de Navarra; CIMA and CIBERONC, Pamplona, Spain.
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Medical Oncology, INCLIVA Health Research Institute, Valencia, Spain.
- CIBERONC, Madrid, Spain.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Rohrberg, K. S., Melero, I., F Sanmamed, M., Muñoz-Couselo, E., Cervantes, A., Gambardella, V., Greillier, L., Garrido, P., Kim, H. R., Lee, D. H., Italiano, A., Cassier, P. A., Hiret, S., Deva, S., Kim, T. M., Blumenschein, G. R., Løvendahl Eefsen, R., Henick, B. S., Perro, M., …, & Moreno, V. (2026). First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012729
Vancouver
Rohrberg KS, Melero I, F Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, et al. First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-012729
BibTeX
@article{Rohrberg2026,
author = {Rohrberg, Kristoffer Staal and Melero, Ignacio and F Sanmamed, Miguel and Muñoz-Couselo, Eva and Cervantes, Andrés and Gambardella, Valentina and Greillier, Laurent and Garrido, Pilar and Kim, Hye Ryun and Lee, Dae Ho and Italiano, Antoine and Cassier, Philippe Alexandre and Hiret, Sandrine and Deva, Sanjeev and Kim, Tae Min and Blumenschein, George R and Løvendahl Eefsen, Rikke and Henick, Brian S and Perro, Mario and Umaña, Pablo and Peixoto, Antonio and Lauener, Laura and Weber, Patrick and Seeber, Stefan and Klein, Christian and Higgins, Brian and Guidi, Micol and Kraus, Dominik and Mücke, Merlind and Heichinger, Christian and Tran, Vu-Long and Schmid, Daniela and Michielin, Francesca and Liu, Ting and McIntyre, Christine and Kao, Henry and Codarri Deak, Laura and Markert, Christoph and Moreno, Victor},
title = {First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-012729}
}
EUVIMED